Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
Conjugated to a detectable label or radioisotope or radionuclide or heavy metal-containing compound (Class 530/391.3)
Conjugated to a cytotoxic agent, drug, or other biologically-active substance (Class 530/391.7)
  • Sp35 Antibodies and Uses Thereof
    Publication number: 20130336991
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Sha MI, R. Blake PEPINSKY, Zhaohui SHAO, Christilyn GRAFF
  • Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
    Patent number: 8609818
    Abstract: The present invention relates generally to anti-FN14 antibodies. In particular, the anti-FN14 antibodies described herein are useful for the treatment of diseases, such as a variety of cancers, associated with expression of FN14.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: December 17, 2013
    Assignee: Omeros Corporation
    Inventors: John Benjamin Leppard, Christi L Wood, W Jason Cummings, Munehisa Yabuki, Nancy Maizels, Daniel S Allison, Larry W Tjoelker
  • Anti-hepcidin-25 selective antibodies and uses thereof
    Patent number: 8609817
    Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: December 17, 2013
    Assignee: Eli Lilly and Company
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
  • Extracellular serine protease
    Patent number: 8609819
    Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 17, 2013
    Assignee: Board of Trutees of the University of Arkansas
    Inventors: Timothy J O'Brien, Lowell J Underwood, John Beard, Kazushi Shigemasa
  • Human monoclonal antibodies to O8E
    Patent number: 8609816
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: December 17, 2013
    Assignee: Medarex, L.L.C.
    Inventors: Alan J. Korman, Mark J. Selby, Li-Sheng Lu, Alison Witte, Haichun Huang
  • NANOPARTICLE MEDIATED GENE THERAPY, DIAGNOSTIC PRODUCTS AND THERAPEUTIC PRODUCTS FOR BREAST CANCER
    Publication number: 20130330279
    Abstract: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target cell types apoptosis and correspond to Y predefined target parameters associated with Z predefined target cell types in connection with treatment of at least one of the following breast cancer, glioblastoma, head and neck cancer, pancreatic cancer, lung cancer, cancer of the nervous system, gastrointestinal cancer, prostate cancer, ovarian cancer, kidney cancer, retina, cancer, skin cancer, liver cancer, genital.
    Type: Application
    Filed: December 22, 2012
    Publication date: December 12, 2013
    Applicant: NNANOAXIS, LLC
    Inventors: Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Kamisetti
  • ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40
    Publication number: 20130330344
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 12, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW MALCOLM NESBITT, ANDREW GEORGE POPPLEWELL, STEVAN GRAHAM SHAW, DIANA SHPEKTOR, YI ZHANG
  • Immunoassay reagents and methods of use thereof
    Patent number: 8603765
    Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: December 10, 2013
    Assignee: Biocare Medical, LLC.
    Inventor: David Tacha
  • Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
    Patent number: 8604169
    Abstract: A novel gene 251P5G2 and its encoded protein, and variants thereof, are described wherein 251P5G2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 251P5G2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 251P5G2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 251P5G2 can be used in active or passive immunization.
    Type: Grant
    Filed: December 31, 2009
    Date of Patent: December 10, 2013
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Aya Jakobovits, Mary Faris, Wangmao Ge
  • Anti-integrin immunoconjugates, methods and uses
    Patent number: 8603483
    Abstract: The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: December 10, 2013
    Assignees: Janssen Biotech, Inc., Immunogen, Inc.
    Inventors: Qiming Chen, Mohit Trikha, Robert J. Lutz, Rita M. Steeves, Godfrey Amphlett
  • METHODS AND KITS FOR DETECTION OF 5-HYDROXYMETHYLCYTOSINE
    Publication number: 20130323728
    Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosme (5hmC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.
    Type: Application
    Filed: October 20, 2011
    Publication date: December 5, 2013
    Applicant: OSLO UNIVERSITETSSYKEHUS HF
    Inventors: Adam Brian Robertson, John Arne Dahl, Arne Klungland
  • METHODS AND COMPOSITIONS USING KLOTO-FGF FUSION POLYPEPTIDES
    Publication number: 20130324458
    Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.
    Type: Application
    Filed: May 29, 2013
    Publication date: December 5, 2013
    Inventors: David GLASS, Shou-Ih HU
  • Anti CEACAM1 antibodies and methods of using same
    Patent number: 8598322
    Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: December 3, 2013
    Assignees: Tel Hashomer Medical Research Infrastucture and Services Ltd., Ramot At Tel Aviv University Ltd.
    Inventors: Gal Markel, Rona Ortenberg
  • OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES
    Publication number: 20130315935
    Abstract: This invention concerns an oligomeric receptor-ligand pair member in general and an oligomeric MHC-peptide complex in particular and a method of labeling, detecting and separating mammalian T cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell. The invention further concerns related pharmaceutical and diagnostic compositions and processes.
    Type: Application
    Filed: December 11, 2012
    Publication date: November 28, 2013
    Applicant: PROIMUNNE LIMITED
    Inventor: Nikolai Franz Gregor SCHWABE
  • LUTEINIZING-HORMONE LIGAND AND LIGAND-GONADOTROPHIN COMPLEX
    Publication number: 20130315928
    Abstract: The invention relates to a ligand of a luteinizing hormone (LH), characterized in that it comprises the paratope of an ovine anti-LH antibody of which the variable domain of the heavy chain contains the following CDRs: —VH-CDR1, defined by the sequence GYTFTNYW (SEQ ID NO: 13); —VH-CDR2, defined by the sequence IYPGGGYT (SEQ ID NO: 14); —VH-CDR3, defined by the sequence ARTPLYGSSYGGFAY (SEQ ID NO: 15); and the variable domain of the light chain contains the following CDRs: —VL-CDR1, defined by the sequence QGISNY (SEQ ID NO: 16); —VL-CDR2, defined by the sequence YTS; —VL-CDR3, defined by the sequence QQYSKLPWT (SEQ ID NO: 17). The invention also relates to a ligand-gonadotrophin (LH, hCG, FSH) complex. The ligand or the complex according to the invention can be used to induce ovulation in a female mammal.
    Type: Application
    Filed: November 21, 2011
    Publication date: November 28, 2013
    Inventors: Marie-Christine Maurel, Eric Reiter, Florian Guillou, Nicolas Aubrey
  • PCSK9 ANTAGONISTS
    Publication number: 20130315927
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Application
    Filed: February 10, 2012
    Publication date: November 28, 2013
    Applicants: Novartis AG, IRM LLC
    Inventors: Joshua Goldstein, Steven Bruce Cohen, Andrew Schumacher, David Langdon Yowe
  • Compositions against cancer antigen LIV-1 and uses thereof
    Patent number: 8591863
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: November 26, 2013
    Assignee: Abbvie Biotherapeutics Inc.
    Inventors: Debbie Law, Kurt Gish
  • Antibodies for detecting or monitoring a malignant plasma cell disease
    Patent number: 8592561
    Abstract: The present invention is directed to antibodies having specificity for a heavy chain class at the same time as having specificity for a first light chain. Such antibodies can be used in a method of detecting or monitoring a malignant plasma cell disease comprising determining in a sample the ratio between the relative amounts of immunoglobulins having: (i) a heavy chain class bound to ? light chains; and (ii) immunoglobulins having the same heavy chain class but bound to ? light chains.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: November 26, 2013
    Assignee: The Binding Site Group Limited
    Inventor: Arthur R. Bradwell
  • Thiazolidine Linker for the Conjugation of Drugs to Antibodies
    Publication number: 20130309257
    Abstract: In one aspect, there is provided a protein-drug conjugate compound comprising a protein covalently attached by a linker to one or more drug moieties, wherein the linker has a half-life of from 1 hour to 50 hours in phosphate buffered saline at 37° C. A carbonyl derivative of LU103793 is also described that can be used in a protein-drug conjugate compound comprising an antibody covalently attached by a linker to the drug moiety comprising, consisting or consisting essentially of the carbonyl derivative.
    Type: Application
    Filed: March 25, 2013
    Publication date: November 21, 2013
    Applicant: Philogen S.P.A.
    Inventor: Casi Giulio
  • Genetic products differentially expressed in tumors and the use thereof
    Patent number: 8586047
    Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: November 19, 2013
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
  • Dual variable domain immunoglobulins and uses thereof
    Patent number: 8586714
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: November 19, 2013
    Assignee: ABBVIE, Inc.
    Inventors: Tariq Ghayur, Junjian Liu, Sharmila Manoj, Susan E. Brophy
  • EPHB3-specific antibody and uses thereof
    Patent number: 8586716
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: November 19, 2013
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jeff Hsu, Linda Masat, Judy Abraham, Masahisa Handa, Siew Schleyer
  • Real-Time Adaptive Immune System and Method
    Publication number: 20130303960
    Abstract: The interface between nanotechnology and biological systems is used to synthetically replicate the body's vital, innate, immune functions with targeted precision. Through the creation and use of complexed nanodiamonds (or other particles) with capture agents in a flow-through return apparatus or in an analytic/diagnostic tool, the invention provides individualized treatment of blood-borne pathogens and disease spectrums and rapid, individualized diagnostics. The invention can be used, for example, to clear blood-borne pathogens during initial infections prior to tissue sequestration in real time, to decrease overwhelming numbers of bacterial/viral/cytokine load during life threatening infectious conditions, to super sensitize the immune system to a variety of conditions-cancer markers, vaccinates, etc.
    Type: Application
    Filed: January 5, 2012
    Publication date: November 14, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Angela Courtney, Abigail Spinner
  • MORPHOLOGICALLY AND SIZE UNIFORM MONODISPERSE PARTICLES AND THEIR SHAPE-DIRECTED SELF-ASSEMBLY
    Publication number: 20130302358
    Abstract: Monodisperse particles having: a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology are disclosed. Due to their uniform size and shape, the monodisperse particles self assemble into superlattices. The particles may be luminescent particles such as down-converting phosphor particles and up-converting phosphors. The monodisperse particles of the invention have a rare earth-containing lattice which in one embodiment may be an yttrium-containing lattice or in another may be a lanthanide-containing lattice. The monodisperse particles may have different optical properties based on their composition, their size, and/or their morphology (or shape).
    Type: Application
    Filed: October 3, 2011
    Publication date: November 14, 2013
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INTELLIGENT MATERIAL SOLUTIONS, INC.
    Inventors: Joshua E. Collins, Howard Y. Bell, Xingchen Ye, Christopher Murray
  • Methods and Reagents for Preparing Multifunctional Probes
    Publication number: 20130295640
    Abstract: Multifunctional probes are synthesized in a single step using peptide scaffold-based multifunctional single-attachment-point reagents. To obtain multifunctional probes of the invention, a substrate (e.g., a nanoparticle, polymer, antibody, protein, low molecular weight compound, drug, etc.) is reacted with a multifunctional single-attachment-point (MSAP) reagent. The MSAP reagents can include three components: (i) a peptide scaffold, (ii) a single chemically reactive group on the peptide scaffold for reaction of the MSAP with a substrate having a complementary reactive group, and (iii) multiple functional groups on the peptide scaffold. The peptide scaffold can include any number of residues; however, for ease of synthesis and reproducibility in clinical trials, it is preferred to limit the residues in the peptide to 20 or less.
    Type: Application
    Filed: July 9, 2013
    Publication date: November 7, 2013
    Inventors: Lee Josephson, Elisabeth Garanger
  • TRUNCATED HUMAN VITAMIN D BINDING PROTEIN AND MUTATION AND FUSION THEREOF AND RELATED MATERIALS AND METHODS OF USE
    Publication number: 20130295593
    Abstract: Vitamin D binding proteins (DBP), in particular truncated DBP and mutated, truncated DBP, as well as fusion proteins thereof, nucleic acid molecules encoding same, vectors, host cells, and methods, kits and solid supports for determining the total amount of 25-hydroxy vitamin D2 and 25-hydroxy vitamin D3 in a test sample.
    Type: Application
    Filed: December 23, 2012
    Publication date: November 7, 2013
    Inventors: Christian Beckert, Susan E. Brophy, Jonathan Grote, Dagang Huang, Jan Schultess, Bailin Tu
  • Novel Curcumin and Tetrahydrocurcumin Derivatives
    Publication number: 20130296527
    Abstract: The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.
    Type: Application
    Filed: July 15, 2013
    Publication date: November 7, 2013
    Applicant: Research Foundation of the City University of New York
    Inventors: Krishnaswami Raja, Probal Banerjee, Andrew Auerbach, Wei Shi, William L'Amoreaux
  • Cleavable vaccine compositions and uses thereof and methods of making and using the same
    Patent number: 8575319
    Abstract: The invention relates to methods for making vaccines using linkages that are cleavable under lysosomal processing conditions, and vaccine compositions obtained therefrom. In some embodiments, the vaccines comprise a tumor antigen, an immunogenic carrier and a linker covalently linking the tumor antigen and the immunogenic carrier by a thio ether linkage. Vaccines of preferred embodiments can be used against a cellular proliferative disease that is characterized by the tumor antigen.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: November 5, 2013
    Assignee: The Regents of the University of California
    Inventor: John M. Timmerman
  • BINDING AGENT
    Publication number: 20130289251
    Abstract: A binding agent of the Formula A-a?:a-S-b:b?-B:X(n), wherein A as well as B is a monovalent binder, a?:a as well as b:b? is a binding pair wherein a? and a do not interfere with the binding of b to b? and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a?, a, b, b? or S, (n) is an integer and at least 1, - represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Inventors: Andreas Gallusser, Dieter Heindl, Michael Schraeml, Christoph Seidel, Herbert von der Eltz
  • Method of covalently modifying proteins with organic molecules to prevent aggregation
    Patent number: 8569463
    Abstract: A system and method for preventing protein aggregation is developed by covalent modification of proteins with organic molecules that can preserve the native protein folding. Proteins are covalently modified with sugar alcohols or cyclodextrins (organic Kosmotropes) or other small molecule drugs by water-driven bioorganic reactions in water. In the water-driven bioorganic reactions, the reagent is stable in water and can modify lysine residues or cysteine residue of a protein at physiological conditions with high yield and fast rate. Proteins and antibodies will be modified by non-natural sugar alcohols. As a result, the efficacy of protein drugs (reduction in aggregation and enzymatic degradation, and increase in blood stream life time) may be improved.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: October 29, 2013
    Assignee: Syracuse University
    Inventors: Yan-Yeung Luk, DaWei Cui, Debjyoti Bandyopadhyay, Deepali Prashar, Preeti Sejwal, Karen Simon
  • Anti-IL-12/IL-23 antibodies
    Patent number: 8563697
    Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: October 22, 2013
    Assignee: Cephalon Australia Pty. Ltd.
    Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
  • MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF
    Publication number: 20130272964
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: May 20, 2013
    Publication date: October 17, 2013
    Inventors: WILLIAM DALL'ACQUA, LESLIE S. JOHNSON, ELIZABETH SALLY WARD OBER
  • Detection of Degradation Products of Feline NT-proBNP
    Publication number: 20130274453
    Abstract: A method for determining the amount of NT-proBNP in blood samples from felines. The method includes detecting degradation products of feline NT-proBNP by various methods, including using antibodies, kits and devices.
    Type: Application
    Filed: June 14, 2013
    Publication date: October 17, 2013
    Inventors: Mahalakshmi Yerramilli, Michael Atkinson, Murthy V.S.N. Yerramilli
  • HUMANIZED EGFR ANTIBODIES
    Publication number: 20130273033
    Abstract: The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.
    Type: Application
    Filed: August 10, 2011
    Publication date: October 17, 2013
    Applicant: GLYCOTOPE GMBH
    Inventors: Steffen Goletz, Antje Danielczyk
  • POLYPEPTIDES THAT BIND TO HUMAN COMPLEMENT COMPONENT C5
    Publication number: 20130273052
    Abstract: The present disclosure relates to, inter alia, C5-binding polypeptides and use of the polypeptides in methods for treating or preventing complement-associated disorders. Also featured are therapeutics kits containing one or more of the C5-binding polypeptides and means for administering the polypeptides to a subject.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 17, 2013
    Applicant: ALEXION PHARMACEUTICALS, INC.
    Inventors: David Gies, Jeffrey W. Hunter, Jeremy P. Springhorn
  • ANTI-CEACAM6 ANTIBODIES AND USES THEREOF
    Publication number: 20130272958
    Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for CEACAM6 and their use as therapeutic or diagnostic tools. Specifically, the present invention is directed to antibodies or fragments thereof specific for a linear epitope of CEACAM6. In vivo and in vitro methods of diagnosis as well as therapeutic methods are also described.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 17, 2013
    Inventors: Jianbing Zhang, Toya Nath Baral, Yanal Murad
  • Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
    Patent number: 8557601
    Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: October 15, 2013
    Assignee: The Regents of the University of California
    Inventors: Kenneth N. Raymond, Jide Xu, Evan G. Moore, Eric J. Werner
  • Folate receptor 1 antibodies and immunoconjugates and uses thereof
    Patent number: 8557966
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: October 15, 2013
    Assignee: ImmunoGen, Inc.
    Inventors: Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
  • Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
    Publication number: 20130266579
    Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.
    Type: Application
    Filed: March 8, 2013
    Publication date: October 10, 2013
    Inventors: Ge Wei, Gregory I. Frost, Lei Huang, H. Michael Shepard, Daniel Edward Vaughn
  • ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FROM A SAMPLE USING SAME
    Publication number: 20130266930
    Abstract: The present disclosure is directed to antibody-linked immuno-sedimentation agent, the antibody being linked to a sedimentation agent by a non-antigen binding region of the antibody, and a method of isolating a target from a sample using the antibody-linked immuno-sedimentation agent. The methods involve forming a mixture including a sample with an antibody linked immuno-sedimentation agent and red blood cells under conditions sufficient to form red blood cell rouleaux and allow antibody-antigen binding.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Applicant: CytoSed, Inc.
    Inventor: Warren L. Dinges
  • Human antibodies against hepatitis C virus (HCV) and uses thereof
    Patent number: 8551484
    Abstract: Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: October 8, 2013
    Assignee: University of Massachusetts
    Inventors: Donna M. Ambrosino, William D. Thomas, Jr., Gregory J. Babcock, Teresa Broering, Susan Sloan
  • Anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 8545850
    Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: October 1, 2013
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • ANTI-CXCR3 ANTIBODIES
    Publication number: 20130251733
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 26, 2013
    Applicant: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • METHOD AND SYSTEM TO REMOVE SOLUBLE TNFR1, TNFR2 AND IL2 IN PATIENTS
    Publication number: 20130251672
    Abstract: A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.
    Type: Application
    Filed: May 15, 2013
    Publication date: September 26, 2013
    Applicant: Biopheresis Technologies, Inc.
    Inventor: M. Rigdon LENTZ
  • FLUORESCENT COMPOUNDS
    Publication number: 20130251637
    Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Application
    Filed: December 20, 2011
    Publication date: September 26, 2013
    Applicants: DYOMICS GMBH, PIERCE BIOTECHNOLOGY, INC.
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
  • CHIMERIC RABBIT/HUMAN ROR1 ANTIBODIES
    Publication number: 20130251642
    Abstract: The invention relates to antibodies having specificity for human ROR1, compositions thereof, and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with aberrant ROR1 expression.
    Type: Application
    Filed: November 30, 2011
    Publication date: September 26, 2013
    Applicant: The United States of America, as represented by the secretary, Department of Heath and Human Servi
    Inventors: Christoph Rader, Jiahui Yang
  • NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20130251720
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: October 9, 2012
    Publication date: September 26, 2013
    Applicant: GENENTECH, INC.
    Inventors: HILARY CLARK, DAN EATON, LINO GONZALEZ, JR., JANE GROGAN, JASON A. HACKNEY, KRISTIN HARDEN, XIN YU
  • SELECTIVE REMOVAL OF AGE-MODIFIED CELLS FOR TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20130243785
    Abstract: A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.
    Type: Application
    Filed: September 27, 2011
    Publication date: September 19, 2013
    Inventor: Lewis Gruber
  • NOVEL HUMAN ULIP/CRMP PROTEIN AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF CANCERS AND PARANEOPLASTIC NEUROLOGICAL SYNDROMES
    Publication number: 20130243755
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SED ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Application
    Filed: January 15, 2013
    Publication date: September 19, 2013
    Applicant: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventor: Institut National De La Santa Et De La Recherche Medicale (INSERM)
  • VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA
    Publication number: 20130245234
    Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
    Type: Application
    Filed: January 10, 2013
    Publication date: September 19, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM